HRTX - Heron Therapeutics highlights promising data from ZYNRELEF postoperative pain trials

Heron Therapeutics (HRTX) posts new analysis evaluating the efficacy and safety of ZYNRELEF extended-release solution in adults aged 65 years and older undergoing bunionectomy and hernia repair from the Phase 3 EPOCH 1 and EPOCH 2 studies.The analysis showed that 58% of bunionectomy and 87% of hernia repair patients on ZYNRELEF required no opioids to manage their postoperative pain through 72 hours following surgery.The company also highlighted that throughout the 72-hour period, the mean pain intensity never rose above the mild range.ZYNRELEF was well tolerated with a safety profile similar to that for bupivacaine.Shares up nearly 1% post market.Heron Therapeutics announced the launch of ZYNRELEF in the U.S., earlier this month.

For further details see:

Heron Therapeutics highlights promising data from ZYNRELEF postoperative pain trials